COVID-19 Impact on Global Molecular Diagnostics Cancer Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Molecular Diagnostics Cancer Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Molecular Diagnostics Cancer Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Pharmacogenomic Diagnosis
  • 1.4.3 Liquid Biopsy
  • 1.4.4 Other
• 1.5 Market by Application
  • 1.5.1 Global Molecular Diagnostics Cancer Market Share by Application: 2020 VS 2026
  • 1.5.2 Respiratory Cancer
  • 1.5.3 Cancer of Digestive System
  • 1.5.4 Cancer of Urinary System
  • 1.5.5 Cancer of Circulatory System
  • 1.5.6 Motor System Cancer
  • 1.5.7 Reproductive System Cancer
  • 1.5.8 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Molecular Diagnostics Cancer Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Molecular Diagnostics Cancer Industry
    • 1.6.1.1 Molecular Diagnostics Cancer Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Molecular Diagnostics Cancer Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Molecular Diagnostics Cancer Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Molecular Diagnostics Cancer Market Perspective (2015-2026)
• 2.2 Molecular Diagnostics Cancer Growth Trends by Regions
  • 2.2.1 Molecular Diagnostics Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Molecular Diagnostics Cancer Historic Market Share by Regions (2015-2020)
  • 2.2.3 Molecular Diagnostics Cancer Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Molecular Diagnostics Cancer Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Molecular Diagnostics Cancer Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Molecular Diagnostics Cancer Players by Market Size
  • 3.1.1 Global Top Molecular Diagnostics Cancer Players by Revenue (2015-2020)
  • 3.1.2 Global Molecular Diagnostics Cancer Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Molecular Diagnostics Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Molecular Diagnostics Cancer Market Concentration Ratio
  • 3.2.1 Global Molecular Diagnostics Cancer Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Molecular Diagnostics Cancer Revenue in 2019
• 3.3 Molecular Diagnostics Cancer Key Players Head office and Area Served
• 3.4 Key Players Molecular Diagnostics Cancer Product Solution and Service
• 3.5 Date of Enter into Molecular Diagnostics Cancer Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Molecular Diagnostics Cancer Historic Market Size by Type (2015-2020)
• 4.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Type (2021-2026)

5 Molecular Diagnostics Cancer Breakdown Data by Application (2015-2026)

• 5.1 Global Molecular Diagnostics Cancer Market Size by Application (2015-2020)
• 5.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Molecular Diagnostics Cancer Market Size (2015-2020)
• 6.2 Molecular Diagnostics Cancer Key Players in North America (2019-2020)
• 6.3 North America Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 6.4 North America Molecular Diagnostics Cancer Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Molecular Diagnostics Cancer Market Size (2015-2020)
• 7.2 Molecular Diagnostics Cancer Key Players in Europe (2019-2020)
• 7.3 Europe Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 7.4 Europe Molecular Diagnostics Cancer Market Size by Application (2015-2020)

8 China

• 8.1 China Molecular Diagnostics Cancer Market Size (2015-2020)
• 8.2 Molecular Diagnostics Cancer Key Players in China (2019-2020)
• 8.3 China Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 8.4 China Molecular Diagnostics Cancer Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Molecular Diagnostics Cancer Market Size (2015-2020)
• 9.2 Molecular Diagnostics Cancer Key Players in Japan (2019-2020)
• 9.3 Japan Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 9.4 Japan Molecular Diagnostics Cancer Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Molecular Diagnostics Cancer Market Size (2015-2020)
• 10.2 Molecular Diagnostics Cancer Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 10.4 Southeast Asia Molecular Diagnostics Cancer Market Size by Application (2015-2020)

11 India

• 11.1 India Molecular Diagnostics Cancer Market Size (2015-2020)
• 11.2 Molecular Diagnostics Cancer Key Players in India (2019-2020)
• 11.3 India Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 11.4 India Molecular Diagnostics Cancer Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Molecular Diagnostics Cancer Market Size (2015-2020)
• 12.2 Molecular Diagnostics Cancer Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Molecular Diagnostics Cancer Market Size by Type (2015-2020)
• 12.4 Central & South America Molecular Diagnostics Cancer Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche Molecular Diagnostics Cancer Introduction
  • 13.1.4 Roche Revenue in Molecular Diagnostics Cancer Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Danaher
  • 13.2.1 Danaher Company Details
  • 13.2.2 Danaher Business Overview and Its Total Revenue
  • 13.2.3 Danaher Molecular Diagnostics Cancer Introduction
  • 13.2.4 Danaher Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.2.5 Danaher Recent Development
• 13.3 Siemens
  • 13.3.1 Siemens Company Details
  • 13.3.2 Siemens Business Overview and Its Total Revenue
  • 13.3.3 Siemens Molecular Diagnostics Cancer Introduction
  • 13.3.4 Siemens Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.3.5 Siemens Recent Development
• 13.4 Abbott Laboratories
  • 13.4.1 Abbott Laboratories Company Details
  • 13.4.2 Abbott Laboratories Business Overview and Its Total Revenue
  • 13.4.3 Abbott Laboratories Molecular Diagnostics Cancer Introduction
  • 13.4.4 Abbott Laboratories Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.4.5 Abbott Laboratories Recent Development
• 13.5 ICON Plc
  • 13.5.1 ICON Plc Company Details
  • 13.5.2 ICON Plc Business Overview and Its Total Revenue
  • 13.5.3 ICON Plc Molecular Diagnostics Cancer Introduction
  • 13.5.4 ICON Plc Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.5.5 ICON Plc Recent Development
• 13.6 AstraZeneca
  • 13.6.1 AstraZeneca Company Details
  • 13.6.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.6.3 AstraZeneca Molecular Diagnostics Cancer Introduction
  • 13.6.4 AstraZeneca Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.6.5 AstraZeneca Recent Development
• 13.7 MDxHealth
  • 13.7.1 MDxHealth Company Details
  • 13.7.2 MDxHealth Business Overview and Its Total Revenue
  • 13.7.3 MDxHealth Molecular Diagnostics Cancer Introduction
  • 13.7.4 MDxHealth Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.7.5 MDxHealth Recent Development
• 13.8 Invitae
  • 13.8.1 Invitae Company Details
  • 13.8.2 Invitae Business Overview and Its Total Revenue
  • 13.8.3 Invitae Molecular Diagnostics Cancer Introduction
  • 13.8.4 Invitae Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.8.5 Invitae Recent Development
• 13.9 PlexBio
  • 13.9.1 PlexBio Company Details
  • 13.9.2 PlexBio Business Overview and Its Total Revenue
  • 13.9.3 PlexBio Molecular Diagnostics Cancer Introduction
  • 13.9.4 PlexBio Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.9.5 PlexBio Recent Development
• 13.10 Thermo Fisher Scientific
  • 13.10.1 Thermo Fisher Scientific Company Details
  • 13.10.2 Thermo Fisher Scientific Business Overview and Its Total Revenue
  • 13.10.3 Thermo Fisher Scientific Molecular Diagnostics Cancer Introduction
  • 13.10.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 13.10.5 Thermo Fisher Scientific Recent Development
• 13.11 Guardant Health
  • 10.11.1 Guardant Health Company Details
  • 10.11.2 Guardant Health Business Overview and Its Total Revenue
  • 10.11.3 Guardant Health Molecular Diagnostics Cancer Introduction
  • 10.11.4 Guardant Health Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.11.5 Guardant Health Recent Development
• 13.12 Biocartis
  • 10.12.1 Biocartis Company Details
  • 10.12.2 Biocartis Business Overview and Its Total Revenue
  • 10.12.3 Biocartis Molecular Diagnostics Cancer Introduction
  • 10.12.4 Biocartis Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.12.5 Biocartis Recent Development
• 13.13 Bio-Techne
  • 10.13.1 Bio-Techne Company Details
  • 10.13.2 Bio-Techne Business Overview and Its Total Revenue
  • 10.13.3 Bio-Techne Molecular Diagnostics Cancer Introduction
  • 10.13.4 Bio-Techne Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.13.5 Bio-Techne Recent Development
• 13.14 Merck
  • 10.14.1 Merck Company Details
  • 10.14.2 Merck Business Overview and Its Total Revenue
  • 10.14.3 Merck Molecular Diagnostics Cancer Introduction
  • 10.14.4 Merck Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.14.5 Merck Recent Development
• 13.15 Foundation Medicine
  • 10.15.1 Foundation Medicine Company Details
  • 10.15.2 Foundation Medicine Business Overview and Its Total Revenue
  • 10.15.3 Foundation Medicine Molecular Diagnostics Cancer Introduction
  • 10.15.4 Foundation Medicine Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.15.5 Foundation Medicine Recent Development
• 13.16 10X Genomics
  • 10.16.1 10X Genomics Company Details
  • 10.16.2 10X Genomics Business Overview and Its Total Revenue
  • 10.16.3 10X Genomics Molecular Diagnostics Cancer Introduction
  • 10.16.4 10X Genomics Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.16.5 10X Genomics Recent Development
• 13.17 Biodesix
  • 10.17.1 Biodesix Company Details
  • 10.17.2 Biodesix Business Overview and Its Total Revenue
  • 10.17.3 Biodesix Molecular Diagnostics Cancer Introduction
  • 10.17.4 Biodesix Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.17.5 Biodesix Recent Development
• 13.18 CytoTrack
  • 10.18.1 CytoTrack Company Details
  • 10.18.2 CytoTrack Business Overview and Its Total Revenue
  • 10.18.3 CytoTrack Molecular Diagnostics Cancer Introduction
  • 10.18.4 CytoTrack Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.18.5 CytoTrack Recent Development
• 13.19 GenomOncology
  • 10.19.1 GenomOncology Company Details
  • 10.19.2 GenomOncology Business Overview and Its Total Revenue
  • 10.19.3 GenomOncology Molecular Diagnostics Cancer Introduction
  • 10.19.4 GenomOncology Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.19.5 GenomOncology Recent Development
• 13.20 Luminex
  • 10.20.1 Luminex Company Details
  • 10.20.2 Luminex Business Overview and Its Total Revenue
  • 10.20.3 Luminex Molecular Diagnostics Cancer Introduction
  • 10.20.4 Luminex Revenue in Molecular Diagnostics Cancer Business (2015-2020)
  • 10.20.5 Luminex Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer